Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CPBIO Holding CoCAIHF 71 EBITDA Margin % is 19.10% as of Dec. 2025, which is 17% below its 10-year median of 22.96. GuruFocus rates CAIHF with a GF Score™ of 71/100 and a GF Value™ of $0.14. The stock has 4 warning signs investors should review. Among 961 Drug Manufacturers companies, CPBIO Holding Co ranks worse than 53.59% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. CPBIO Holding Co's EBITDA for the
three
months ended in Dec. 2025 was $20.1 Mil. CPBIO Holding Co's Revenue for the
three
months ended in Dec. 2025 was $105.4 Mil. Therefore, CPBIO Holding Co's EBITDA margin for the quarter that ended in Dec. 2025 was 19.10%.
CPBIO Holding Co (OTCPK:CAIHF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
CPBIO Holding Co EBITDA Margin % Related Terms
CPBIO Holding Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for CPBIO Holding Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CPBIO Holding Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CPBIO Holding Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CPBIO Holding Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where CPBIO Holding Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CPBIO Holding Co (CAIHF) has a EBITDA Margin % of 19.10% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CPBIO Holding Co and its competitors. This is 17% below median its historical median of 22.96. Over the past decade, CPBIO Holding Co's EBITDA Margin % has ranged from 3.25 to 32.96. According to the industry distribution chart, CPBIO Holding Co ranks #515 out of 961 companies in the Drug Manufacturers industry, placing it in the top 53.6%.
Is CPBIO Holding Co's EBITDA Margin % too high?
CPBIO Holding Co's current EBITDA Margin % of 19.10% is 17% below median its 10-year median of 22.96. Over the past 10 years, this metric has ranged from a low of 3.25 to a high of 32.96. The Drug Manufacturers industry median EBITDA Margin % is 12.39. CPBIO Holding Co's value of 19.10% is 54.2% above this industry median. Based on the distribution chart, CPBIO Holding Co ranks #515 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, CPBIO Holding Co has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.
How does CPBIO Holding Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CPBIO Holding Co ranks #515 out of 961 companies for EBITDA Margin %. This places CPBIO Holding Co in the lower half of its industry. The industry median EBITDA Margin % is 12.39. CPBIO Holding Co's value of 19.10% is 54.2% above this benchmark. Historically, CPBIO Holding Co's own EBITDA Margin % has ranged from 3.25 to 32.96 over the past decade. While the company's 10-year median is 22.96 vs. the industry median of 12.39, CPBIO Holding Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CPBIO Holding Co's current EBITDA Margin % of 19.10% is 54.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on CPBIO Holding Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CPBIO Holding Co's current EBITDA Margin % is 19.10%, which is 17% below median its own 10-year median of 22.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CPBIO Holding Co stock overvalued right now?
CPBIO Holding Co (CAIHF) has a current EBITDA Margin % of 19.10%. The stock's GF Value™ is $0.14, compared to a current price of $0.28 — trading 100% above its estimated fair value. The current EBITDA Margin % is 19.10%, which is 17% below median its 10-year median of 22.96 and 54.2% above the Drug Manufacturers industry median of 12.39. CPBIO Holding Co's overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For CPBIO Holding Co (CAIHF), the current EBITDA Margin % is 19.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CPBIO Holding Co (CAIHF) Overvalued in 2026?
Based on GuruFocus' analysis, CPBIO Holding Co stock appears to be overvalued.
The current stock price of $0.28 is trading 100% above its estimated GF Value™ of $0.14.
Key valuation signals for CAIHF:
EBITDA Margin %: 19.10% (17% below median its 10-year median of 22.96)
GF Value™: $0.14 vs. price of $0.28 (100% above fair value)
Industry Position: 54.2% above the Drug Manufacturers median (#515 of 961)
No single metric tells the full story. See the CAIHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chia Tai Enterprises International Ltd is engaged in the manufacture and sale of animal health products and chlortetracycline (CTC). The group has two reportable segments: Biotech Business and Investment Business. The Biotech Business segment is involved in the manufacture and/or sale of animal health products and chlortetracycline. The Investment Business segment is engaged in the trading of machinery and the manufacture and sale of automotive parts through the group's joint ventures and associates. It generates the majority of its revenue from the Biotech Business segment. Its geographical segments are Mainland China, which generates key revenue, Asia Pacific (excluding mainland China), the Americas, Europe, and Others.
71GF Score
Get the complete analysis for CAIHF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAIHF has been successfully added to your 
